文献速递心脑血管急症重症综合管理与镇静镇痛

胶质纤维酸性蛋白对中重度创伤性脑损伤患者的预后价值:系统评价与荟萃分析

Prognostic Value of Glial Fibrillary Acidic Protein in Patients With Moderate and Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论中重度创伤性脑损伤患者血清胶质纤维酸性蛋白水平在预后不良者中显著升高,可能有助于床旁预后评估。

该系统评价与荟萃分析检索MEDLINE、Embase、CENTRAL和BIOSIS等数据库,纳入报告中重度创伤性脑损伤患者胶质纤维酸性蛋白水平与格拉斯哥结局量表或扩展格拉斯哥结局量表及死亡率关系的队列研究。共纳入15项研究(n=1,070),其中9项进入荟萃分析(n=701)。血清胶质纤维酸性蛋白水平与格拉斯哥结局量表评分≤3或扩展格拉斯哥结局量表评分≤4显著相关(6项研究:几何均值比4.98,95%CI 2.19-11.13;I=94%),与死亡率也显著相关(7项研究:几何均值比8.13,95%CI 3.89-17.00;I=99%)。作者认为胶质纤维酸性蛋白有潜力用于临床床旁协助预后评估,进一步研究应关注包括组织生物标志物在内的多模态方法。

要点

  • 中重度创伤性脑损伤患者血清胶质纤维酸性蛋白水平在预后不良(格拉斯哥结局量表≤3或扩展格拉斯哥结局量表≤4)者中显著升高:几何均值比4.98(95%CI 2.19-11.13)。
  • 血清胶质纤维酸性蛋白水平与死亡风险显著相关:几何均值比8.13(95%CI 3.89-17.00)。
  • 荟萃分析异质性很高:预后不良结局分析I=94%,死亡率分析I=99%。
  • 作者认为胶质纤维酸性蛋白有潜力用于临床床旁协助预后评估,进一步研究应关注多模态方法。

适用人群与场景

  • 中重度创伤性脑损伤患者,纳入研究的队列需包含≥4例中重度创伤性脑损伤患者并报告胶质纤维酸性蛋白水平与格拉斯哥结局量表或扩展格拉斯哥结局量表及死亡率的关系。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析;共检索7,765条文献,纳入15项研究(n=1,070)进行系统评价,其中9项(n=701)进入荟萃分析。
  • 主要终点:血清胶质纤维酸性蛋白水平与格拉斯哥结局量表评分≤3或扩展格拉斯哥结局量表评分≤4的关联有统计学意义(6项研究:几何均值比4.98,95%CI 2.19-11.13;I=94%)。
  • 次要终点:血清胶质纤维酸性蛋白水平与死亡率的关联有统计学意义(7项研究:几何均值比8.13,95%CI 3.89-17.00;I=99%)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入队列研究。
  • 局限:预后不良结局分析异质性I=94%,死亡率分析异质性I=99%。
  • 作者结论:胶质纤维酸性蛋白有潜力用于临床床旁协助预后评估;进一步研究应关注包括组织生物标志物在内的多模态方法。

对床旁实践的改变

  • 作者认为血清胶质纤维酸性蛋白水平有潜力用于临床床旁协助中重度创伤性脑损伤患者的预后评估,但当前证据异质性高,尚不能据此形成具体推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Biomarkers have been suggested as potential prognostic predictors following a moderate or severe traumatic brain injury but their prognostic accuracy is still uncertain. The objective of this systematic review is to assess the ability of the glial fibrillary acidic protein to predict prognosis in patients with moderate or severe traumatic brain injury.

DATA SOURCES: MEDLINE, Embase, CENTRAL, and BIOSIS electronic databases and conference abstracts, bibliographies of selected studies, and narrative reviews were searched.

STUDY SELECTION: Pairs of reviewers identified eligible studies. Cohort studies including greater than or equal to four patients with moderate or severe traumatic brain injury and reporting glial fibrillary acidic protein levels according to the outcomes of interest, namely Glasgow Outcome Scale or Extended Glasgow Outcome Scale, and mortality, were eligible.

DATA EXTRACTION: Pairs of reviewers independently extracted data from the selected studies using a standardized case report form. Mean levels were log-transformed, and their differences were pooled with random effect models. Results are presented as geometric mean ratios. Methodologic quality, risk of bias, and applicability concerns of the included studies were assessed.

DATA SYNTHESIS: Seven-thousand seven-hundred sixty-five citations were retrieved of which 15 studies were included in the systematic review (n = 1,070), and nine were included in the meta-analysis (n = 701). We found significant associations between glial fibrillary acidic protein serum levels and Glasgow Outcome Scale score less than or equal to 3 or Extended Glasgow Outcome Scale score less than or equal to 4 (six studies: geometric mean ratio 4.98 [95% CI, 2.19-11.13]; I = 94%) and between mortality (seven studies: geometric mean ratio 8.13 [95% CI, 3.89-17.00]; I = 99%).

CONCLUSIONS: Serum glial fibrillary acidic protein levels were significantly higher in patients with an unfavorable prognosis. Glial fibrillary acidic protein has a potential for clinical bedside use in helping for prognostic assessment. Further research should focus on multimodal approaches including tissue biomarkers for prognostic evaluation in critically ill patients with traumatic brain injury.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Shemilt M, Boutin A, Lauzier F, et al. Prognostic Value of Glial Fibrillary Acidic Protein in Patients With Moderate and Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Crit Care Med. 2019. PMID: 30889029. doi:10.1097/CCM.0000000000003728

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。